JP2016508153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508153A5 JP2016508153A5 JP2015552050A JP2015552050A JP2016508153A5 JP 2016508153 A5 JP2016508153 A5 JP 2016508153A5 JP 2015552050 A JP2015552050 A JP 2015552050A JP 2015552050 A JP2015552050 A JP 2015552050A JP 2016508153 A5 JP2016508153 A5 JP 2016508153A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- heavy chain
- motomeko
- proteins
- human igg1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751045P | 2013-01-10 | 2013-01-10 | |
| DKPA201300019 | 2013-01-10 | ||
| US61/751,045 | 2013-01-10 | ||
| DKPA201300019 | 2013-01-10 | ||
| PCT/EP2013/064330 WO2014006217A1 (en) | 2012-07-06 | 2013-07-05 | Dimeric protein with triple mutations |
| EPPCT/EP2013/064330 | 2013-07-05 | ||
| PCT/EP2014/050340 WO2014108483A1 (en) | 2013-01-10 | 2014-01-09 | Inert format |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508153A JP2016508153A (ja) | 2016-03-17 |
| JP2016508153A5 true JP2016508153A5 (enExample) | 2017-02-16 |
| JP6604851B2 JP6604851B2 (ja) | 2019-11-13 |
Family
ID=49881390
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519244A Active JP6514103B2 (ja) | 2012-07-06 | 2013-07-05 | 三重変異を有する二量体タンパク質 |
| JP2015552050A Active JP6604851B2 (ja) | 2013-01-10 | 2014-01-09 | 不活性フォーマット |
| JP2022075888A Pending JP2022115955A (ja) | 2012-07-06 | 2022-05-02 | 三重変異を有する二量体タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519244A Active JP6514103B2 (ja) | 2012-07-06 | 2013-07-05 | 三重変異を有する二量体タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022075888A Pending JP2022115955A (ja) | 2012-07-06 | 2022-05-02 | 三重変異を有する二量体タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11180572B2 (enExample) |
| EP (3) | EP2869845B1 (enExample) |
| JP (3) | JP6514103B2 (enExample) |
| CN (1) | CN104736174B (enExample) |
| AU (4) | AU2013285355A1 (enExample) |
| BR (1) | BR112015000167B1 (enExample) |
| PL (1) | PL2943507T3 (enExample) |
| SG (2) | SG10201605703TA (enExample) |
| SI (1) | SI2943507T1 (enExample) |
| WO (2) | WO2014006217A1 (enExample) |
Families Citing this family (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10515A (enExample) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PL4160212T3 (pl) | 2008-01-15 | 2024-08-12 | The Board Of Trustees Of The Leland Stanford Junior University | Markery komórek macierzystych ostrej białaczki szpikowej |
| FI3056514T4 (fi) | 2008-01-15 | 2025-10-06 | Univ Leland Stanford Junior | Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi |
| TWI700293B (zh) | 2008-04-11 | 2020-08-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗體 |
| PL2560993T3 (pl) * | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| PT2869845T (pt) * | 2012-07-06 | 2019-12-09 | Genmab Bv | Proteína dimérica com mutações triplas |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| EP2970508A4 (en) * | 2013-03-15 | 2016-12-14 | Permeon Biologics Inc | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE |
| JP6426693B2 (ja) | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| EP3628685A1 (en) | 2013-04-29 | 2020-04-01 | F. Hoffmann-La Roche AG | Human fcrn-binding modified antibodies and methods of use |
| US20160068613A1 (en) | 2013-04-29 | 2016-03-10 | Hoffmann-La Roche Inc. | Fc-receptor binding modified asymmetric antibodies and methods of use |
| HUE048722T2 (hu) * | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| KR102225489B1 (ko) | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| WO2015107026A1 (en) * | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| CA2931979A1 (en) * | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding properties |
| CA2932364A1 (en) * | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with improved protein a-binding |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| ES2900898T3 (es) | 2014-04-07 | 2022-03-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecíficos inmunoactivadores |
| CA2947157A1 (en) | 2014-05-13 | 2015-11-19 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| SI3215528T1 (sl) * | 2014-11-06 | 2019-11-29 | Hoffmann La Roche | Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe |
| EP3215524B1 (en) | 2014-11-06 | 2021-01-13 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
| TWI656133B (zh) | 2014-12-19 | 2019-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法 |
| UA120286C2 (uk) * | 2015-01-08 | 2019-11-11 | Ґенмаб А/С | Біспецифічне антитіло проти cd3 і cd20 |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| MX2017012805A (es) * | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| EP3305322A4 (en) * | 2015-06-05 | 2018-12-26 | Chugai Seiyaku Kabushiki Kaisha | Combined use of immune activators |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| AU2016293073B2 (en) | 2015-07-15 | 2022-12-22 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| FI3325011T6 (fi) | 2015-07-24 | 2023-05-11 | Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi | |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| WO2017093448A1 (en) * | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3411409B1 (en) | 2016-01-10 | 2025-10-08 | Neotx Therapeutics Ltd. | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy |
| JP2019511458A (ja) * | 2016-01-27 | 2019-04-25 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 組み換えＩｇＧ Ｆｃ多量体 |
| CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| TWI781098B (zh) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
| CA3030636A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| MX2019000887A (es) * | 2016-07-22 | 2019-09-04 | Gliknik Inc | Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc. |
| KR20250036943A (ko) | 2016-08-02 | 2025-03-14 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
| IL308091B1 (en) | 2016-09-13 | 2026-01-01 | Allergan Inc | Protein-free stabilized Clostridium toxin preparations |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| WO2018083126A1 (en) | 2016-11-01 | 2018-05-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| JP7231549B2 (ja) * | 2017-02-06 | 2023-03-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| KR20190115057A (ko) * | 2017-02-10 | 2019-10-10 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018178396A1 (en) | 2017-03-31 | 2018-10-04 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| JP7257335B2 (ja) | 2017-05-25 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用 |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| MX2019014407A (es) * | 2017-06-07 | 2020-02-05 | Genmab Bv | Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados. |
| WO2019025545A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE |
| ES2911243T3 (es) * | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11529425B2 (en) * | 2017-09-07 | 2022-12-20 | Dingfu Biotarget Co., Ltd. | Immunoconjugates comprising signal regulatory protein alpha |
| KR20200059249A (ko) | 2017-09-21 | 2020-05-28 | 유엠씨 우트레크트 홀딩 비.브이. | 신경아세포종의 치료를 위한 항-gd2 항체 |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| AU2018347607B2 (en) | 2017-10-14 | 2025-08-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CN118772287A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| CN111971298B (zh) | 2018-03-12 | 2025-06-20 | 健玛保 | 抗体 |
| WO2019175368A1 (en) * | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| IL277375B2 (en) | 2018-03-15 | 2025-08-01 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
| AU2019240247B2 (en) * | 2018-03-21 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Fc variant compositions and methods of use thereof |
| PE20201346A1 (es) * | 2018-04-13 | 2020-11-25 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk |
| EP3788074A1 (en) | 2018-05-03 | 2021-03-10 | Genmab B.V. | Antibody variant combinations and uses thereof |
| WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| MA52951A (fr) * | 2018-06-22 | 2021-04-28 | Genmab Holding B V | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020012038A1 (en) * | 2018-07-13 | 2020-01-16 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| CN120865412A (zh) * | 2018-07-13 | 2025-10-31 | 根马布股份公司 | Cd38抗体变体及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3873930A4 (en) * | 2018-10-23 | 2022-12-07 | Magenta Therapeutics, Inc. | FC-ALIMINATED ANTIBODY DRUG CONJUGATES (ADCS) AND THEIR USES |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US12331119B2 (en) * | 2019-02-22 | 2025-06-17 | Wuhan Yzy Biopharma Co., Ltd. | Modified Fc fragment, antibody comprising same, and application thereof |
| US20220211767A1 (en) * | 2019-04-27 | 2022-07-07 | Figene, Llc | Enhancement of fibroblast therapeutic activity by t cell modulation |
| GB201910900D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
| AU2020335928A1 (en) | 2019-08-30 | 2022-02-17 | Agenus Inc. | Anti-CD96 antibodies and methods of use thereof |
| WO2021048423A1 (en) | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| CN112646041B (zh) * | 2019-10-12 | 2023-11-10 | 上海睿智化学研究有限公司 | 包含抗体ch3域的异源二聚体及含其的抗体、融合蛋白 |
| US20220411529A1 (en) * | 2019-11-06 | 2022-12-29 | Genmab B.V. | Antibody variant combinations and uses thereof |
| PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| KR20220130724A (ko) * | 2020-01-16 | 2022-09-27 | 젠맵 에이/에스 | Cd38 항체의 제제 및 그의 용도 |
| JP2023513952A (ja) * | 2020-02-19 | 2023-04-04 | アディボ ゲーエムベーハー | 改変Ｆｃ領域 |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| CA3168613A1 (en) | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
| WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP2023540248A (ja) | 2020-08-26 | 2023-09-22 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法 |
| CN116472060A (zh) * | 2020-09-02 | 2023-07-21 | 健玛保 | 抗体疗法 |
| CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| JP2023542291A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| MX2023003749A (es) | 2020-10-02 | 2023-04-24 | Genmab As | Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3). |
| CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| MX2023008302A (es) | 2021-01-13 | 2023-09-25 | Visterra Inc | Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos. |
| CA3210971A1 (en) * | 2021-03-12 | 2022-09-15 | Bart-Jan DE KREUK | Non-activating antibody variants |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| CN117255800A (zh) * | 2021-04-28 | 2023-12-19 | 恩格姆生物制药公司 | 具有抗体恒定区变体的结合分子的多聚化 |
| EP4334359A1 (en) | 2021-05-07 | 2024-03-13 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
| WO2022241235A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
| EP4399227A1 (en) | 2021-09-06 | 2024-07-17 | Genmab A/S | Antibodies capable of binding to cd27, variants thereof and uses thereof |
| US11814437B2 (en) * | 2021-10-08 | 2023-11-14 | Genmab A/S | Antibodies binding to CD30 and CD3 |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| AU2023269546A1 (en) | 2022-05-12 | 2024-11-14 | BioNTech SE | Binding agents capable of binding to cd27 in combination therapy |
| AU2023269545A1 (en) | 2022-05-12 | 2024-11-14 | BioNTech SE | Binding agents capable of binding to cd27 in combination therapy |
| CA3258004A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/HSA BONDING MOLECULES AND METHODS OF USE |
| KR20250054799A (ko) * | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| EP4680632A2 (en) | 2023-03-17 | 2026-01-21 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| US12351650B2 (en) | 2023-06-30 | 2025-07-08 | Genmab A/S | Antibodies binding to fibroblast activation protein alpha and death receptor 4 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025133707A1 (en) | 2023-12-19 | 2025-06-26 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
| WO2025133694A1 (en) | 2023-12-20 | 2025-06-26 | argenx BV | Fcrn/hsa-binding molecules and methods of use |
| EP4644413A1 (en) | 2024-05-03 | 2025-11-05 | Genmab B.V. | Binding agents having altered fc-mediated effector functions |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ES2199216T3 (es) | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE348175T1 (de) | 1992-07-17 | 2007-01-15 | Dana Farber Cancer Inst Inc | Method eder intrazellularen bindung von zielgerichteten molekülen |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| FR2717187B1 (fr) | 1994-03-10 | 1996-05-31 | Transgene Sa | Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt. |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0975355A2 (en) * | 1996-06-14 | 2000-02-02 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| ES2237420T5 (es) | 1999-04-15 | 2010-03-03 | Crucell Holland B.V. | Produccion de proteina recombinante en una celula humana. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| ES2344070T3 (es) | 2001-07-04 | 2010-08-17 | Chromagenics B.V. | Secuencias de adn con actividad anti-represora. |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| ES2373947T3 (es) | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
| MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
| EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
| CN1942483B (zh) * | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| ES2426817T3 (es) * | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| JP4487068B2 (ja) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| US20100104564A1 (en) | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| WO2007039818A2 (en) | 2005-05-09 | 2007-04-12 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| EP1899477A4 (en) | 2005-07-01 | 2010-01-20 | Medimmune Inc | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS |
| CA2617907A1 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| SI1973950T1 (sl) | 2006-01-05 | 2015-01-30 | Genentech, Inc. | Anti-EphB4 protitelesa in postopki njihove uporabe |
| CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
| JP2009529331A (ja) * | 2006-03-10 | 2009-08-20 | マクロジェニクス，インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
| EP2087111A2 (en) | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
| CA2685675C (en) * | 2007-05-01 | 2016-02-16 | Research Development Foundation | Immunoglobulin fc libraries |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| WO2009017394A1 (en) | 2007-08-01 | 2009-02-05 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例 |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| RU2509085C2 (ru) * | 2008-01-28 | 2014-03-10 | Медиммун Лимитед | Стабилизированные антитела против ангиопоэтина-2 и их применение |
| EP2250279B1 (en) | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| PT3456190T (pt) | 2008-06-27 | 2022-02-15 | Merus Nv | Animal murino transgénico produtor de anticorpo |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| DE102008039957A1 (de) | 2008-08-27 | 2010-03-04 | Continental Automotive Gmbh | Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| EP3524620A1 (en) | 2008-10-14 | 2019-08-14 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2742568C (en) | 2008-11-03 | 2017-09-26 | Syntarga B.V. | Novel cc-1065 analogs and their conjugates |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| WO2010132872A1 (en) | 2009-05-15 | 2010-11-18 | Novimmune S.A | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| MX2012006406A (es) | 2009-12-04 | 2012-07-25 | Genentech Inc | Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos. |
| KR20130005264A (ko) | 2010-01-11 | 2013-01-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-ｃｄ200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들 |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| ES2993335T3 (en) | 2010-03-10 | 2024-12-27 | Genmab As | Monoclonal antibodies against c-met |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| US9714294B2 (en) | 2010-05-27 | 2017-07-25 | Genmab A/S | Monoclonal antibodies against HER2 epitope |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| AU2011267106B2 (en) | 2010-06-15 | 2015-05-14 | Genmab A/S | Human antibody drug conjugates against tissue factor |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102003075B1 (ko) * | 2011-02-23 | 2019-07-23 | 에프. 호프만-라 로슈 아게 | 인간 il33r에 대한 항체 및 이의 용도 |
| ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| CN107827985A (zh) * | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| KR20240123420A (ko) | 2013-01-10 | 2024-08-13 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| HUE048722T2 (hu) | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| UA120286C2 (uk) | 2015-01-08 | 2019-11-11 | Ґенмаб А/С | Біспецифічне антитіло проти cd3 і cd20 |
| AU2016293073B2 (en) | 2015-07-15 | 2022-12-22 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| CN120865412A (zh) | 2018-07-13 | 2025-10-31 | 根马布股份公司 | Cd38抗体变体及其用途 |
-
2013
- 2013-07-05 AU AU2013285355A patent/AU2013285355A1/en not_active Abandoned
- 2013-07-05 WO PCT/EP2013/064330 patent/WO2014006217A1/en not_active Ceased
- 2013-07-05 EP EP13735254.8A patent/EP2869845B1/en active Active
- 2013-07-05 US US14/413,178 patent/US11180572B2/en active Active
- 2013-07-05 CN CN201380045878.0A patent/CN104736174B/zh active Active
- 2013-07-05 SG SG10201605703TA patent/SG10201605703TA/en unknown
- 2013-07-05 SG SG11201408646VA patent/SG11201408646VA/en unknown
- 2013-07-05 BR BR112015000167-0A patent/BR112015000167B1/pt active IP Right Grant
- 2013-07-05 JP JP2015519244A patent/JP6514103B2/ja active Active
-
2014
- 2014-01-09 SI SI201431575T patent/SI2943507T1/sl unknown
- 2014-01-09 US US14/760,157 patent/US10590206B2/en active Active
- 2014-01-09 EP EP14700200.0A patent/EP2943507B1/en active Active
- 2014-01-09 JP JP2015552050A patent/JP6604851B2/ja active Active
- 2014-01-09 WO PCT/EP2014/050340 patent/WO2014108483A1/en not_active Ceased
- 2014-01-09 EP EP20159405.8A patent/EP3738979A1/en active Pending
- 2014-01-09 PL PL14700200T patent/PL2943507T3/pl unknown
-
2018
- 2018-05-17 AU AU2018203510A patent/AU2018203510A1/en not_active Abandoned
-
2020
- 2020-02-06 US US16/783,720 patent/US11485796B2/en active Active
- 2020-04-07 AU AU2020202410A patent/AU2020202410A1/en not_active Abandoned
-
2022
- 2022-05-02 JP JP2022075888A patent/JP2022115955A/ja active Pending
- 2022-09-22 US US17/950,350 patent/US20230322947A1/en active Pending
- 2022-10-27 AU AU2022259785A patent/AU2022259785B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508153A5 (enExample) | ||
| US8592562B2 (en) | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects | |
| TWI788286B (zh) | 三特異性和/或三價結合蛋白 | |
| JP2020048564A5 (enExample) | ||
| US11111305B2 (en) | Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex | |
| JP2017505121A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| CN108367075A (zh) | 4-1bb结合蛋白及其用途 | |
| JP2014520788A5 (enExample) | ||
| AU2010343056A1 (en) | Ron binding constructs and methods of use thereof | |
| WO2018016881A1 (ko) | 이중 특이성 단백질 및 이의 제조 방법 | |
| JP2016520598A5 (enExample) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| JP2014533243A5 (enExample) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2016512539A (ja) | ヒト化抗ｎ２抗体 | |
| JP2024073580A (ja) | Ｂｔｌａ抗体 | |
| CN111448217A (zh) | 双特异性抗原结合构建体 | |
| AU2022357501A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv | |
| Wang et al. | New directions for half-life extension of protein therapeutics: the rise of antibody Fc domains and fragments | |
| AU2015202560A1 (en) | Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects | |
| Tiwari et al. | Immunoglobulin: Structure and Function | |
| HK40092434A (zh) | Btla抗体 | |
| RU2020130794A (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение |